December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

14.76 -0.24 (-1.60%)
Delayed Quote Updated: 3:46 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lyell Immunopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma To Participate in November Investor Events
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in May Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in March Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Issued on behalf of GT Biopharma, Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in September Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.